Amylon Therapeutics is dedicated to developing therapies for rare genetic disorders of the central nervous system (CNS) using their innovative RNA Modulation Technology. By altering the splicing of pre-mRNA with antisense oligonucleotides (ASOs), they counteract the effects of disease-causing mutations. Their lead research program focuses on Hereditary Cerebral Hemorrhage with Amyloidosis Dutch Type (HCHWA-D), the most common form of hereditary cerebral amyloid angiopathy (CAA). With a strong management team and world-class advisory boards, Amylon aims to build a sustainable drug development platform to tackle CNS diseases and provide hope for patients in need.